An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was...

|By:, SA News Editor

An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was safe and effective at treating COPD. The agency's pulmonary-allergy advisory committee is still reviewing the drug and has to vote on whether the product should be marketed, but today's positive vote makes it likely the panel will vote affirmatively to support approval. Shares remain halted.